Mesalazine in chronic idiopathic urticaria

Evaluation of the therapeutic effects of Mesalazine in patients with chronic idiopathic urticaria

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT138710041520N1

Enrollment

Registered

2009-04-03

Start date

2008-06-26

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Idiopathic urticaria. Idiopathic Urticaria

Interventions

Mesalazine 500 mg Bid for 2 months.

Mesalazine 500 mg Bid for 2 months

Eligibility

Sex/Gender

All

Age

12 Years to 75 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria: new cases, the patients without proper control with antihistamines Exclusion Criteria : children under 12y, pregnant ladies or women with breast feeding, underlying diseases, 5-ASA sensitivity, G6PD deficiency

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Decrease in Symptoms of the patients. Timepoint: 15 dayas and 1 month and 2 month. Method of measurement: Symptom Severity indices and Quality of Life Questionaire.	—

Secondary

Measure	Time frame
Improvement in Quality of Life of the patients. Timepoint: 2 month. Method of measurement: Quality of life Questionaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAlireza Abdollahee

Shiraz University of Medical Sciences

abdolaha@sums.ac.ir & alireza2358@gmail.com+98 71 1730 3431

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026